Shire
Shire delivers record revenues
February 16, 2015Sales and Marketing ADHD, AbbVie, Shire, Viropharma, Vyvanse, intuniv, lialda
Shire has posted strong growth in its full-year results, showing that the company is faring well even after the collapse …
MRC Technology hires senior head from Shire
February 11, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Edward Bliss, MRC, Shire
UK medical research charity MRC Technology has appointed Dr Edward Bliss to the new role of general counsel and company …
Shire drug approved for binge eating disorder
February 2, 2015Sales and Marketing ADHD, FDA, Shire, Vyvanse, binge, eating, lisdexamfetamine dimesylate, obesity
Shire has become the first company to gain FDA approval for a treatment for binge eating disorder (BED) in adults …
Shire lifted by rare disease approvals
January 26, 2015Sales and Marketing HGT-2310, Hunter syndrome, SHP609, Shire, fast track, idursulfase-IT, rare disease
Shire’s investigational drug for a rare neurological disease has been accepted into the FDA’s fast-track approval process. The drug, SHP609, …
Shire buys rare-disease firm NPS Pharma
January 12, 2015Sales and Marketing AbbVie, Shire, gattex, natpara, nps, nps pharma
Shire is to acquire rare diseases firm NPS Pharma to enhance its profile following the collapse of its deal with …
PM Society names pharma prize finalists
December 17, 2014Medical Communications, Sales and Marketing GSK, Mundipharma, Shire, VCCP Health, digital awards, pm society
The finalists for the PM Society Awards have been announced today as pharma and med comms agencies gear up to …
Working Life: Shire’s Mark Rus
November 10, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shire, Working Life, mark rus, neuroscience
How did you find your way into your current role? After completing an MSc in Economics at the London School …
Shire interim chief financial officer resigns
October 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Shire, james bowling, merger
Shire’s interim chief financial officer James Bowling has left the firm for water company Severn Trent following the collapse of …
AbbVie ditches Shire as tax deal falters
October 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Obama, Shire, US government, tax, tax inversion
Tax rule changes coming from the US government have forced the collapse of a multi-billion dollar deal between Humira manufacturer …
AbbVie reconsiders Shire deal over tax laws
October 15, 2014Medical Communications, Sales and Marketing AbbVie, Abbott, Obama, Shire, US, mergers, tax
AbbVie will reconsider its planned $54.6 billion takeover of Shire in light of new US proposals designed to curb companies …
Shire accused of dishonest marketing in US
September 25, 2014Medical Communications, Sales and Marketing Adderall XR, Department of Justice, DoJ, Shire, US, amphetamine, dextroamphetamine
Shire will pay a fine of $56.5 million to resolve a string of legal allegations in the US surrounding the …
AbbVie/Shire deal under threat from tax laws
August 7, 2014Medical Communications, Sales and Marketing AbbVie, AstraZeneca, Pfizer, Shire, tax inversion
The £32 billion deal between AbbVie and Irish specialist biotech Shire could be under threat from new rules in the …
AbbVie agrees to buy Shire for £32bn
July 18, 2014Sales and Marketing AbbVie, Abbott, Humira, Shire, merger, new abbvie, takeover
Shire has accepted a £32 billion takeover deal from AbbVie after months of rejections and uncertainty. The firm, which is …
AbbVie a step closer to Shire takeover
July 14, 2014Sales and Marketing ADHD, AbbVie, Abbott, Humira, Shire, hep C, takeover
Shire is recommending a new offer from suitor AbbVie that could finally see the US giant merge with the Dublin-based …
AbbVie makes fourth Shire offer
July 9, 2014Sales and Marketing AbbVie, Abbott, Shire, buyout, merger
The AbbVie/Shire takeover saga rumbles on, with AbbVie raising its bid for the Ireland-based biopharma specialist to $51.5 billion. The …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
